Clinical Trials · NCT07141914
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 285,327
- Start date
- Aug 2025
- Locations
- 1 site, United States
- Primary endpoint
- Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event)